Topics AMED signs research collaboration memorandum with Canadian Institutes of Health Research


The President of the Japan Agency for Medical Research and Development (AMED), Dr. Yoshinao Mishima, has signed a Memorandum of Cooperation (MoC) with Dr. Michael Strong, the President of the Canadian Institutes of Health Research (CIHR). The CIHR is the Canadian Government’s lead funding agency for health and medical research, and AMED and CIHR have jointly held two workshops to date, in February 2017 and March 2018, agreeing to promote research that combines advanced technologies and biomedicine. Having signed this MoC, AMED aims to promote collaborative research based on equal partnership between the two agencies, further paving the way for joint scientific events. In order to prevent any possible transmission of COVID-19, Dr. Mishima and Dr. Strong signed the MoC without meeting face-to-face, and signed copies were exchanged by post. (Effective date of signature: June 19, 2020)

Dr. Michael Strong, President of the Canadian Institutes of Health Research, signing the MoC at his home in Ottawa (left) and Dr. Yoshinao Mishima, President of AMED, signing the MoC at his office in Tokyo (right).

Based on the MoC, AMED and CIHR will promote collaborative research relevant to Advancing Epigenetic Technologies. AMED has announced a Japan-Canada joint grant call for proposals for research up to three years in duration (call open from June 22 until September 15) under the framework of the Strategic International Collaborative Research Program (SICORP). Canada possesses many world-class research centers of excellence in the field of epigenetics, and we look forward to receiving a large number of competitive research proposals.
Furthermore, the scope of the MoC also includes cooperative activities through personnel exchanges, joint seminars, workshops, and other scientific meetings.


Last updated 07/10/20